Table 5.

Therapeutic decision making in participants with methamphetamine-associated PAH

Treatment	Odds Ratio (95% CI)	P Value
Unadjusted
Digoxin	1.90 (1.04–3.48)	0.038
On PAH-specific treatment	0.77 (0.41–1.43)	0.403
Dual combination	1.36 (0.95–1.95)	0.094
Triple therapy	0.59 (0.36–0.95)	0.031
Parenteral prostacyclin	0.20 (0.10–0.39)	<0.001
Supplemental oxygen	0.47 (0.32–0.70)	<0.001
Adjusted for age, sex, race/ethnicity, education, body mass index, and the time-dependent covariates of 6-minute walk distance and World Health Organization functional class
Digoxin	1.83 (0.91–3.70)	0.091
On PAH-specific treatment	0.73 (0.31–1.71)	0.465
Dual combination	1.23 (0.79–1.92)	0.361
Triple therapy	0.43 (0.24–0.77)	0.005
Parenteral prostacyclin	0.10 (0.04–0.24)	<0.001
Supplemental oxygen	0.49 (0.30–0.81)	0.005

Definition of abbreviations: CI = confidence interval; PAH = pulmonary arterial hypertension.

Data are presented as odds ratio of being on specific therapy with 95% CIs in participants with methamphetamine-associated PAH as compared with participants with idiopathic PAH, as quantified by generalized estimating equations using a Binomial distribution. Models were adjusted for age, sex, race/ethnicity, education, body mass index, and the time-dependent covariates of World Health Organization functional class and 6-minute walk distance. Dual combination therapy represents combination therapy with a phosphodiesterase 5 inhibitor or riociguat, and an endothelin receptor antagonist. Triple therapy represents combination therapy with a phosphodiesterase 5 inhibitor or riociguat, an endothelin receptor antagonist, and any prostacyclin pathway agent.